Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

Core Insights - Orexo AB announced positive pharmacokinetic in-vivo data for a powder-based intranasal semaglutide formulation developed with AmorphOX technology [1][3] - The AmorphOX formulations showed a sevenfold increase in plasma values compared to the oral tablet, although lower than the injectable version [2][7] - The technology allows for needle-free delivery, improved convenience, and potentially better adherence, with extended dosing schedules [3][4] Company Overview - Orexo is a Swedish pharmaceutical company with 30 years of experience in developing improved pharmaceuticals, particularly for opioid use disorder [5] - The company reported total net sales of SEK 590 million in 2024 and has 110 employees [5] - Orexo is listed on Nasdaq Stockholm and available as ADRs on OTCQX market in the US [5] Technology Insights - AmorphOX is a proprietary drug delivery platform that formulates large molecules into powders for intranasal delivery [7][8] - The technology has demonstrated significantly higher plasma concentrations and bioavailability compared to oral formulations [7][8] - AmorphOX aims to prioritize larger molecules like peptides, proteins, and vaccines for more efficient treatment options [4][7] Product Insights - Semaglutide is a GLP-1 receptor agonist used for treating type 2 diabetes and obesity, available in oral and injectable forms [9][10] - Current injectable GLP-1 medications require refrigeration and weekly needle sticks, while oral formulations face bioavailability challenges [10][11] - The AmorphOX intranasal formulation may address these issues by providing a more convenient delivery method [3][4]